Bedel Financial Consulting’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bedel Financial Consulting’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-730	Closed	-$4K	–	760
2022 Q1	$4K	Hold	730	–	–	﹤0.01%	807
2021 Q4	$5K	Hold	730	–	–	﹤0.01%	792
2021 Q3	$7K	Hold	730	–	–	﹤0.01%	735
2021 Q2	$9K	Hold	730	–	–	﹤0.01%	696
2021 Q1	$9K	Hold	730	–	–	﹤0.01%	662
2020 Q4	$11K	Buy	730 +80	+12%	+$937	﹤0.01%	540
2020 Q3	$6K	Hold	650	–	–	﹤0.01%	592
2020 Q2	$6K	Sell	650 -10,000	-94%	-$92.8K	﹤0.01%	565
2020 Q1	$68K	Buy	10,650 +10,000	+1,538%	+$74.2K	0.05%	230
2019 Q4	$5K	Hold	650	–	–	﹤0.01%	593
2019 Q3	$6K	Hold	650	–	–	﹤0.01%	550
2019 Q2	$7K	Hold	650	–	–	﹤0.01%	532
2019 Q1	$6K	Hold	650	–	–	﹤0.01%	551
2018 Q4	$7K	Hold	650	–	–	0.01%	511
2018 Q3	$9K	Hold	650	–	–	0.01%	490
2018 Q2	$9K	Hold	650	–	–	0.01%	492
2018 Q1	$12K	Buy	+650	New	+$13.9K	0.01%	456

Other funds holding SGMO

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RCMU

Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bedel Financial Consulting's SGMO Position: Q2 2022 in Review

Bedel Financial Consulting sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2022, closing a stake of 730 shares — an estimated $4K sold.

Bedel Financial Consulting first reported a position in SGMO in Q1 2018 and held it in 17 quarters. The position peaked at $68K in Q1 2020. 188 funds tracked by Wall St. Rank hold SGMO as of Q2 2022.

Bedel Financial Consulting reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2022 after selling out during the quarter.
Bedel Financial Consulting sold 730 SANGAMO THERAPEUTICS INC shares in Q2 2022, an estimated $4K.
Bedel Financial Consulting first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 17 quarters.
Bedel Financial Consulting's SANGAMO THERAPEUTICS INC position peaked at $68K in Q1 2020.
188 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.